MeSH Browser

MeSH Heading: Levodopa
Tree Number(s): D02.092.311.200.480; D02.455.426.559.389.657.166.175.200.480; D12.125.072.050.685.400.500; D12.125.072.050.875.130.500
Unique ID: D007980
RDF Unique Identifier: http://id.nlm.nih.gov/mesh/D007980
Scope Note: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.
Entry Term(s): 3-Hydroxy-L-tyrosine; Dopaflex; Dopar; L-3,4-Dihydroxyphenylalanine; L-Dopa; Larodopa; Levopa
Pharm Action: Antiparkinson Agents
Dopamine Agents
NLM Classification #: WK 725
Previous Indexing: Dopa (1966-1974)
See Also: Dopamine
Public MeSH Note: 75; was see DOPA 1972-74
Online Note: search DOPA 1972-74
History Note: 75; was see DOPA 1972-74
Date Established: 1975/01/01
Date of Entry: 1999/01/01
Revision Date: 2018/06/30

Allowable Qualifiers: administration & dosage (AD)

adverse effects (AE)

agonists (AG)

analogs & derivatives (AA)

analysis (AN)

antagonists & inhibitors (AI)

biosynthesis (BI)

blood (BL)

cerebrospinal fluid (CF)

chemical synthesis (CS)

chemistry (CH)

classification (CL)

deficiency (DF)

economics (EC)

genetics (GE)

history (HI)

immunology (IM)

isolation & purification (IP)

metabolism (ME)

pharmacokinetics (PK)

pharmacology (PD)

physiology (PH)

poisoning (PO)

radiation effects (RE)

standards (ST)

supply & distribution (SD)

therapeutic use (TU)

toxicity (TO)

urine (UR)

Concept UI: M0012434
Scope Note: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.
Terms: Levodopa Preferred Term
Term UI T023782
Date01/01/1999
LexicalTag NON
ThesaurusID; L-3,4-Dihydroxyphenylalanine
Term UI T023781
Date09/19/1984
LexicalTag NON
ThesaurusID UNK (19XX); 3-Hydroxy-L-tyrosine
Term UI T023784
Date03/25/1994
LexicalTag NON
ThesaurusID NLM (1995); L-Dopa
Term UI T023785
Date06/30/1976
LexicalTag NON
ThesaurusID

Levodopa MeSH Descriptor Data 2024